Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point

JAMA Neurol. 2014 Aug;71(8):947-9. doi: 10.1001/jamaneurol.2014.1120.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Alzheimer Disease / diagnosis*
  • Amyloid beta-Peptides / metabolism*
  • Clinical Trials as Topic / standards*
  • Disease Progression*
  • Female
  • Humans
  • Male
  • Neuropsychological Tests / standards*

Substances

  • Amyloid beta-Peptides